The LBI-CR looks back onto an unusually successful year 2015, which has seen significant progress in organizational aspects, but it is also characterized by an outstanding scientific output in the form of publications and an increasing participation in international research projects. The new annual report of 2015 provides not only a comprehensive scientific overview, but also impressive data that in 2015 the institute surpassed previous years with respect to many output parameters.
In 2015 key researchers of the LBI-CR contributed to 40 publications in peer reviewed journals with a cumulative impact factor of 310. Of these publications eleven were led by key researchers from the LBI-CR and nine of these achieved an IF > 3.
The LBI has recently restructured to prepare for a budget cut by the LBG. For the research program to remain competitive and stable at a high level therefore researchers are increasingly reliant on third party funds. We are therefore proud to report not only that recently researchers obtained prestigious EU funded grants, but also that the contribution of third party funds to the annual budget is stable at a very high level of 600,000 €, which corresponds now to 24% of our total budget.
The FFG has now decided to fund a new project entitled "Identification of novel STAT3/5 inhibitors to interfere with the oncogenic activities of STATs in hematopoietic cancer" in collaboration of Prof. Richard Moriggl of the LBI-CR and Prof. Patrick Gunning of the University Toronto, which aims to identify new compounds blocking STAT function in cancer. STATs are hyper activated in many solid and hematopoietic cancers due to mutations in upstream kinases or point mutations in conserved domains of STAT proteins.
Luisa Schmidt, PhD student in the group of Florian Grebien has received a prestigious DOC fellowship from the Austrian Academy of Sciences. She studies the contribution of the transcription factor C/EBPα to acute myeloid leukemia and is particularly interested in how disease development is influenced by the epigenomic landscape and super-enhancers. Her project aims to elucidate the molecular functions of the leukemia-associated, truncated isoform C/EBPα p30 by exploring its influence on the epigenome.
The Ludwig Boltzmann Gesellschaft (LBG) invited with Prof. Dr. Gerard Evan (Head of Department of Biochemistry, University of Cambridge, UK) (chair), Prof. Dr. Aly Karsan (Department of Pathology and Laboratory Medicine, University of British Columbia; Medical Director, Centre for Clinical Genomics, Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, Canada) Prof. Dr.